Earnings History Data for Halozyme Therapeutics, Inc. (HALO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-05-2025	AH		HALO	Halozyme Therapeutics, Inc.	7,540	1.03	0.89	0.71	Halozyme Therapeutics Non-GAAP EPS of $1.11 beats by $0.17, revenue of $264.9M beats by $34.72M [5/6/2025 4:10 PM]	70.11	10.73 (18.07%)	63.75	4.37 (7.36%)	40.87 - 70.51	8,640,560	1,270,000	31,154
Halozyme Therapeutics Non-GAAP EPS of $1.11 beats by $0.17, revenue of $264.9M beats by $34.72M [5/6/2025 4:10 PM] Halozyme sees strong Q1 2025 growth, raises 2025 revenue guidance to $1.2B-$1.28B [5/6/2025 7:16 PM] HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS [2025-05-06 04:01PM] Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now? [2025-05-06 06:20AM] Halozyme to Participate in the BofA Securities 2025 Healthcare Conference [May-05-25 05:15PM] Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... [2025-05-07 03:19AM] Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates [May-06-25 07:00PM] Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates [May-06-25 05:35PM]
18-02-2025	AH		HALO	Halozyme Therapeutics	7,457	1.19	1.16	0.00	Halozyme Therapeutics Non-GAAP EPS of $1.26 beats by $0.10, revenue of $298M beats by $12.26M [2/18/2025 4:02 PM]	57.67	-0.23 (-0.40%)	58.50	0.60 (1.04%)	35.50 - 65.53	1,864,506	1,040,000	8,195
Halozyme Therapeutics Non-GAAP EPS of $1.26 beats by $0.10, revenue of $298M beats by $12.26M [2/18/2025 4:02 PM] Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products [2/18/2025 7:55 PM] HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS [2025-02-18 04:01PM]
31-10-2024	AH		HALO	Halozyme Therapeutics, Inc.	6,410	1.17	0.93	0.69	Halozyme Therapeutics Non-GAAP EPS of $1.27 beats by $0.27, revenue of $290.1M beats by $37.93M [10/31/2024 4:03 PM]	57.04	6.47 (12.80%)	56.67	6.10 (12.06%)	33.10 - 65.53	2,871,119	1,030,000	59,500
Halozyme Therapeutics Non-GAAP EPS of $1.27 beats by $0.27, revenue of $290.1M beats by $37.93M [10/31/2024 4:03 PM] HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS [2024-10-31 04:01PM]
06-08-2024	AH		HALO	Halozyme Therapeutics, Inc.	7,010	0.85	0.73	0.68	Halozyme Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook [8/6/2024 4:06 PM]	54.15	2.21 (4.25%)	54.55	2.61 (5.03%)	32.83 - 57.08	1,690,642	1,160,000	49,018
Halozyme Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook [8/6/2024 4:06 PM]
07-05-2024	AH		HALO	Halozyme Therapeutics	5,059	0.71	0.69	0.00	Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09, revenue of $195.88M misses by $3.77M [5/7/2024 4:03 PM]	42.07	0.86 (2.09%)	41.30	0.09 (0.22%)	29.85 - 45.00	1,849,084	850,000	3,725
Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09, revenue of $195.88M misses by $3.77M [5/7/2024 4:03 PM]
20-02-2024	AH		HALO	Halozyme Therapeutics, Inc.	4,740	0.75	0.77	0.44	Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M [2/20/2024 4:02 PM]	38.35	2.35 (6.53%)	37.74	1.74 (4.83%)	29.85 - 51.45	2,197,947	1,040,000	11,621
Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M [2/20/2024 4:02 PM]
06-11-2023	AH		HALO	Halozyme Therapeutics, Inc.	4,520	0.69	0.67	0.70	Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line [11/6/2023 4:09 PM]	38.72	3.46 (9.81%)	34.75	-0.51 (-1.45%)	29.85 - 59.46	1,784,974	880,000	31,400
Halozyme, Acumen enter collaboration for Alzheimer's drug candidate [11/6/2023 8:23 AM] Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line [11/6/2023 4:09 PM]
08-08-2023	AH		HALO	Halozyme Therapeutics, Inc.	5,580	0.68	0.59	0.50	Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M [8/8/2023 4:04 PM]	42.57	-0.74 (-1.71%)	45.00	1.69 (3.90%)	29.85 - 59.46	981,239	1,060,000	129
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M [8/8/2023 4:04 PM]
09-05-2023	AH	4:00 PM ET (May 9)	HALO	Halozyme Therapeutics, Inc.	4,200	0.43	0.44	0.43	Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.01, revenue of $162.14M misses by $13.38M [5/9/2023 4:04 PM]	34.50	3.92 (12.82%)	33.00	2.42 (7.91%)	29.85 - 59.46	2,938,805	1,400,000	10,760
Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.01, revenue of $162.14M misses by $13.38M [5/9/2023 4:04 PM] Halozyme gains as Piper Sandler upgrades despite Q1 miss [5/10/2023 9:19 AM]
21-02-2023	AH	4:00 PM ET (Feb 21)	HALO	Halozyme Therapeutics, Inc.	6,660	0.44	0.43	0.39	Halozyme Therapeutics Non-GAAP EPS of $0.48 beats by $0.01, revenue of $181.5M misses by $10.55M [2/21/2023 4:03 PM]	50.04	0.38 (0.77%)	48.00	-1.66 (-3.34%)	32.00 - 59.46	1,129,137	1,050,000	64,460
Halozyme Therapeutics Non-GAAP EPS of $0.48 beats by $0.01, revenue of $181.5M misses by $10.55M [2/21/2023 4:03 PM]
08-11-2022	AH	4:00 PM ET (Nov 8)	HALO	Halozyme Therapeutics, Inc.	6,550	0.70	0.49	0.52	Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23, revenue of $208.98M beats by $17.81M [11/8/2022 4:11 PM]	49.82	3.99 (8.71%)	47.75	1.92 (4.19%)	31.36 - 52.98	2,308,702	980,000	1,432
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23, revenue of $208.98M beats by $17.81M [11/8/2022 4:11 PM] HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS [Nov-08-22 04:01PM] Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings? [Nov-07-22 11:06AM]
09-08-2022	AH	4:00 PM ET (Aug 9)	HALO	Halozyme Therapeutics, Inc.	6,830	0.50	0.47	0.63	Halozyme Therapeutics Non-GAAP EPS of $0.53, revenue of $152.37M; raises FY22 outlook [8/9/2022 4:06 PM]	44.09	0.76 (1.75%)	47.00	3.67 (8.47%)	31.36 - 52.98	1,966,337	1,090,000	2,751
Halozyme Therapeutics Non-GAAP EPS of $0.53, revenue of $152.37M; raises FY22 outlook [8/9/2022 4:06 PM] Shares of Halozyme add ~9% after hours on Q2 revenue rise, raised FY 2022 guidance [8/9/2022 5:57 PM] HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS [Aug-09-22 04:01PM]
10-05-2022	AH	4:00 PM ET (May 10)	HALO	Halozyme Therapeutics, Inc.	5,410	0.43	0.44	0.34	Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M [5/10/2022 4:02 PM]	38.55	0.35 (0.92%)	38.50	0.30 (0.79%)	31.36 - 46.62	1,198,952	1,110,000	1,039
Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M [5/10/2022 4:02 PM] Heska (HSKA) Misses Q1 Earnings and Revenue Estimates [May-09-22 09:35AM] Halozyme Reports First Quarter 2022 Results [May-10-22 04:01PM] Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates [May-10-22 05:25PM] Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues [May-11-22 09:36AM]
22-02-2022	AH	4:00 PM ET (Feb 22)	HALO	Halozyme Therapeutics, Inc.	4,650	0.39	0.35	0.50	Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M [2/22/2022 4:05 PM]	33.77	0.98 (2.99%)	32.79	0.0 (0.00%)	31.36 - 56.40	1,059,509	710,000	14,872
Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M [2/22/2022 4:05 PM] HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS [Feb-22-22 04:01PM] Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates [Feb-22-22 05:25PM] Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues [Feb-23-22 11:31AM]
02-11-2021	AH	4:00 PM ET (Nov 2)	HALO	Halozyme Therapeutics, Inc.	5,440	0.52	0.42	0.25	Halozyme Therapeutics EPS beats by $0.07, beats on revenue [11/2/2021 4:07 PM]	40.05	0.56 (1.42%)	40.66	1.17 (2.96%)	30.07 - 56.40	1,181,948	670,000	8,792
Halozyme Therapeutics EPS beats by $0.07, beats on revenue [11/2/2021 4:07 PM] Darzalex sales royalties help propel Halozyme Therapeutics to Q3 2021 earnings beat [11/2/2021 6:00 PM] Should You Buy Halozyme (HALO) Ahead of Earnings? [Nov-01-21 08:46AM] Halozyme Reports Third Quarter 2021 Results [Nov-02-21 04:01PM] Halozyme Therapeutics (HALO) Q3 Earnings and Revenues Top Estimates [Nov-02-21 05:35PM] Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance [Nov-03-21 10:39AM] Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook [Nov-03-21 11:42AM]
09-08-2021	AH	4:00 PM ET (Aug 9)	HALO	Halozyme Therapeutics, Inc.	5,760	0.63	0.43	0.19	Halozyme Therapeutics EPS beats by $0.22, beats on revenue [8/9/2021 4:05 PM]	41.31	0.87 (2.15%)	46.00	5.56 (13.75%)	25.17 - 56.40	1,663,589	720,000	126,793
Halozyme Therapeutics EPS beats by $0.22, beats on revenue [8/9/2021 4:05 PM] Halozyme Reports Second Quarter 2021 Results [Aug-09-21 04:01PM] Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates [Aug-09-21 05:45PM] Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript [Aug-09-21 10:00PM] Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance [Aug-10-21 09:45AM]
10-05-2021	AH	4:00 PM ET (May 10)	HALO	Halozyme Therapeutics, Inc.	6,830	0.34	0.31	-0.04	Halozyme Therapeutics EPS beats by $0.05, beats on revenue [5/10/2021 4:03 PM]	42.69	-3.41 (-7.41%)	45.32	-0.78 (-1.69%)	22.11 - 56.40	2,123,597	850,000	106
Halozyme Therapeutics EPS beats by $0.05, beats on revenue [5/10/2021 4:03 PM] Halozyme Reports First Quarter 2021 Results [May-10-21 04:01PM] Halozyme Therapeutics (HALO) Tops Q1 Earnings and Revenue Estimates [May-10-21 05:50PM] Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript [May-10-21 11:30PM] Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat [May-11-21 11:09AM]
23-02-2021	AH	4:00 PM ET (Feb 23)	HALO	Halozyme Therapeutics, Inc.	6,720	0.50	0.56	-0.24	Halozyme Therapeutics EPS misses by $0.05, beats on revenue [2/23/2021 4:06 PM]	51.87	4.66 (9.87%)	48.99	1.78 (3.77%)	12.71 - 56.40	10,413,487	1,016,394	35,757
Halozyme Therapeutics EPS misses by $0.05, beats on revenue [2/23/2021 4:06 PM] Halozyme proposes offering of $500M convertible senior notes due 2027 [2/23/2021 4:17 PM] Recap: Halozyme Therapeutics Q4 Earnings [Feb-23-21 04:31PM] Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results [Feb-23-21 04:01PM]
02-11-2020	AH	4:00 PM ET (Nov 2)	HALO	Halozyme Therapeutics, Inc.	3,960	0.25	0.20	-0.17	Halozyme Therapeutics EPS beats by $0.05, beats on revenue [11/2/2020 4:05 PM]	31.69	2.50 (11.58%)	30.50	2.10 (7.39%)	12.71 - 32.62	5,417,568	1,842,380	10,252

10-08-2020	AH	4:00 PM ET (Aug 10)	HALO	Halozyme Therapeutics, Inc.	3,980	0.19	0.25	-0.10	Halozyme Therapeutics EPS misses by $0.04, misses on revenue [8/10/2020 4:08 PM]	28.92	0.28 (0.98%)	27.59	-1.05 (-3.67%)	12.71 - 29.64	587,832	845,797	1,688